LimmaTech Biologics AG
Patricia Martin Killias is an accomplished professional in the field of biotechnology with extensive experience in clinical and regulatory affairs. Since June 2015, Patricia has been serving as the Chief Operating Officer and Managing Director at LimmaTech Biologics AG, where previous roles included Vice President Clinical and Regulatory Affairs and Clinical Director. Prior experience includes Clinical Project Manager at Glycovaxyn AG and Clinical Trial Manager at Cytos Biotechnology AG. Patricia also held the position of Clinical Research Associate at Five Office Ltd. Patricia holds a doctorate in natural sciences (Dr.sc.nat.) from the University of Zürich.
This person is not in any teams
LimmaTech Biologics AG
LimmaTech Biologics AG is a Swiss-based clinical stage biopharmaceutical company. We are advancing our proprietary vaccine pipeline to halt the increasing threat of global infections due to emerging antibiotic resistance (AMR) and sexually transmitted diseases. In addition to our proprietary research, we also develop vaccines together with GSK.